🔗 Visit the ClinicalTrials.gov page for NCT02423512
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Natalizumab induction and maintenance therapy for Crohn's disease. | N Engl J Med | 2005 | 5.36 |
| 2 | Vedolizumab as induction and maintenance therapy for ulcerative colitis. | N Engl J Med | 2013 | 4.75 |
| 3 | Vedolizumab as induction and maintenance therapy for Crohn's disease. | N Engl J Med | 2013 | 3.98 |
| 4 | Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. | Gastroenterology | 2014 | 1.57 |
| 5 | Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease. | Inflamm Bowel Dis | 2013 | 0.77 |